ThinPrep Pap Test Offers Improved Slide Preparation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System for cervical cancer screening has received FDA approval and is now available. The system offers an improved method of preparing Pap smears over the conventional method, leading to fewer retests due to compromised smears and potentially fewer missed abnormalities.

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System forcervical cancer screening has received FDA approval and is nowavailable. The system offers an improved method of preparing Papsmears over the conventional method, leading to fewer retestsdue to compromised smears and potentially fewer missed abnormalities.

With the ThinPrep Pap test, the physician collects the cervicalcells in the traditional way, but rather than smearing a smallportion of the cells onto a slide, the physician rinses the cellsfrom the collection device into a vial filled with preservativesolution. This vial is then sent to the lab where the ThinPrep2000 Processor disperses and filters its contents to reduce mucus,blood, and inflammation, and applies a thin, even layer of cellsto a microscope slide.

Articles in this issue
Princess Diana Helps Raise Over $1 Million for Cancer Research
Study Gives Terminal Patients Option: $18,000 or More Treatment
Proven: Colorectal Screening Cuts Deaths 50%
Virtual Colonoscopy Technique Feasible in Detecting Polyps
Trimetrexate Appears Beneficial in Colorectal Cancer
FDA Liaison Program Answers Patients' Questions About Trials
New Company Joins With RPR To Develop Intrabody Technology
More Insurers Covering ABMT, Despite Lack of Efficacy Data
Klausner Requests Funds for Five Important 'Investment Opportunities' in Cancer Research
CDC Says Teen Smoking Still Rising
ThinPrep Pap Test Offers Improved Slide Preparation
Taxotere for Anthracycline Refractory Advanced Breast Cancer
ODAC Recommends Approval of Aredia for Breast Cancer Bone Mets
Hycamtin Approved For Ovarian Cancer
Gemzar for Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content
Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Tim Cortese
April 15th 2025
Article

The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

Jyoti Mayadev, MD
January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Increased incidence and mortality rates for cervical cancer among rural women in the US may result from barriers to access to care.

Women in Rural Regions Experience Greater Cervical Cancer Incidence/Mortality

Roman Fabbricatore
March 25th 2025
Article

Increased incidence and mortality rates for cervical cancer among rural women in the US may result from barriers to access to care.

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ Years

Julianne Cooley, MS
February 2nd 2023
Podcast

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.

Increased Wait Times Observed for Black/Hispanic Patients With Cervical Cancer

Roman Fabbricatore
March 18th 2025
Article

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.

Cancer Vaccine/Durvalumab Yields Efficacy in HPV+ Cervical Cancer

Cancer Vaccine/Durvalumab Yields Efficacy in HPV+ Cervical Cancer

Ashling Wahner
March 16th 2025
Article

Results from the phase 2 DURBAC trial showed BVAC-C/durvalumab improved response in HPV+ cervical cancer.